Status:
TERMINATED
Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment
Lead Sponsor:
Novartis
Conditions:
Cognitive Symptoms
Eligibility:
All Genders
50-85 years
Phase:
PHASE3
Brief Summary
This study is designed to investigate the efficacy and safety of rivastigmine compared with placebo in patients with mild cognitive impairment (MCI).
Eligibility Criteria
Inclusion
- Males or females who are one year post-menopausal or without childbearing potential
- Between the ages of 50 and 85 years old
- Mild cognitive impairment confirmed by Mini Mental State Examination (MMSE) score between 23 and 27
- Cooperative, able to ingest oral medication, and able to complete all aspects of the study and capable of doing so, either alone or with the aid of a responsible caregiver, according to the investigator's judgement
Exclusion
- A current diagnosis of cerebrovascular disease, any primary neurodegenerative disorder, or any other causes of neuropsychologic disturbances or secondary dementia
- A current diagnosis of epilepsy or depression, or any other diagnosis that may interfere with the patient's response to study medication
- An advanced, severe or unstable disease of any type that may interfere with efficacy evaluations
- Other protocol-defined exclusion criteria may apply.
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
End Date :
May 1 2004
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00134953
Start Date
January 1 2003
End Date
May 1 2004
Last Update
December 17 2007
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.